A single dose of the COVID-19 monoclonal antibody therapy Regeneron, reduced the risk of contracting the virus by 81.6% for up to eight months, following the drug’s administration in a late-stage trial, according to results released by the company on Monday. Katie Johnston reports.

Related posts:

Flynn’s attorney reacts to newly declassified docs in Russia origins probe and what Hillary had to do with it. Florida Power & Light Co. aims to bury 700 neighborhood power lines by 2023 Florida Gambling Deal Gets Final Approval From House ‘Birthplace of Miami,’ Miami Circle Site To Go Through Much-Needed Restoration Disney World Makes Masks Optional For Vaccinated Visitors This Week